{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:07:25Z","timestamp":1789225645603,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jgar.2024.08.013","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T18:11:11Z","timestamp":1726251071000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics"],"prefix":"10.1016","volume":"39","author":[{"given":"Stephen","family":"Hawser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1367-0276","authenticated-orcid":false,"given":"Nimmi","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-6386","authenticated-orcid":false,"given":"Anne Santerre","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.08.013_bib0001","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: a 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.013_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2024.08.013_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/newbio236135a0","article-title":"6\u03b2-Amidinopenicillanic acids\u2014a new group of antibiotics","volume":"236","author":"Lund","year":"1972","journal-title":"Nat New Biol"},{"key":"10.1016\/j.jgar.2024.08.013_bib0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.8.3.271","article-title":"Mecillinam (FL 1060), a 6\u03b2-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro","volume":"8","author":"Tybring","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.1016\/j.jgar.2024.08.013_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jac\/46.suppl_1.35","article-title":"Pivmecillinam in the treatment of urinary tract infections","volume":"46","author":"Nicolle","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0006","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.08.013_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/3.suppl_B.13","article-title":"The mechanism of action of mecillinam","volume":"3","author":"Spratt","year":"1977","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrmicro2677","article-title":"From the regulation of peptidoglycan synthesis to bacterial growth and morphology","volume":"10","author":"Typas","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2024.08.013_bib0009","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.72.8.2999","article-title":"Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12","volume":"72","author":"Spratt","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jgar.2024.08.013_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(03)00235-8","article-title":"Pivmecillinam \u2013 therapy of choice for lower urinary tract infection","volume":"22","author":"Graninger","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.08.013_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u00b7SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.08.013_bib0012","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 11th editor CLSI standard M07. Wayne, Pennsylvania, USA: CLSI; 2018."},{"key":"10.1016\/j.jgar.2024.08.013_bib0013","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 33rd editor CLSI supplement M100 edition. Wayne, Pennsylvania, USA: CLSI; 2023."},{"key":"10.1016\/j.jgar.2024.08.013_bib0014","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: bIGSdb software, the PubMLST.org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jgar.2024.08.013_bib0015","unstructured":"Institut Pasteur MLST databases and software. 2020, https:\/\/bigsdb.pasteur.fr\/n.d."},{"key":"10.1016\/j.jgar.2024.08.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-021-04359-3","article-title":"The role of potentiating mutations in the evolution of pandemic Escherichia coli clones [published online ahead of print 17 November 2021]","author":"Cummins","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.013_bib0017","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/20477724.2022.2121362","article-title":"Global spread and evolutionary convergence of multidrug-resistant and hypervirulent Klebsiella pneumoniae high-risk clones","volume":"117","author":"Arcari","year":"2023","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.jgar.2024.08.013_bib0018","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.44.4.1089-1092.2000","article-title":"A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin","volume":"44","author":"Zhanel","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0019","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1099\/0022-1317-49-8-725","article-title":"Inhibition of virulence factor expression and swarming differentiation in Proteus mirabilis by p-nitrophenylglycerol","volume":"49","author":"Ho","year":"2000","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2024.08.013_bib0020","article-title":"Results from a prospective in vitro study on the mecillinam (amdinocillin) susceptibility of Enterobacterales","volume":"63:e02402-18","author":"Fuchs","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkg028","article-title":"An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOmiddle dotSENS Project","volume":"51","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0022","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","article-title":"Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy","volume":"54","author":"Naber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.jgar.2024.08.013_bib0023","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/jac\/dkac396","article-title":"Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption","volume":"78","author":"Frimodt-M\u00f8ller","year":"2023","journal-title":"J Antimicrobial Chemotherapy"},{"key":"10.1016\/j.jgar.2024.08.013_bib0024","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/AAC.04819-14","article-title":"Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli","volume":"59","author":"Thulin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0025","article-title":"Upregulation of PBP1B and LpoB in cysB mutants confers mecillinam (amdinocillin) resistance in Escherichia coli","volume":"63:e00612-19","author":"Thulin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0026","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12879-016-1797-3","article-title":"Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland","volume":"16","author":"O'Kelly","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.013_bib0027","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12879-017-2250-y","article-title":"Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern \u2013 a hospital based cross sectional study","volume":"17","author":"Fernando","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.013_bib0028","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12879-022-07167-y","article-title":"A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011\u20132020","volume":"22","author":"Dunne","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.013_bib0029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2011.12.012","article-title":"Fourteen years in resistance","volume":"39","author":"Livermore","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.08.013_bib0030","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/jac\/dky230","article-title":"Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study","volume":"73","author":"Bollestad","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.013_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.13387","article-title":"Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by extended spectrum \u03b2eta-lactamase (ESBL) producing Enterobacteriaceae","volume":"73","author":"Raja","year":"2019","journal-title":"Int J Clin Pract"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:25:28Z","timestamp":1734701128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"alternative-id":["S2213716524001656"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.08.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}